以岭药业品牌怎么样 申请店铺

更新时间:2024-10-26
以岭药业是哪个国家的品牌?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
以岭药业怎么样

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://brand.waitui.com/887854f10.html 联系电话:0311-87320288

千城特选小程序码

7×24h 快讯

韩国央行行长称将关注汇率波动,而非设定具体的汇率目标

韩国央行行长李昌镛表示,韩国央行将关注汇率波动,而不是设定具体的汇率目标。如果汇率突破区间,韩国央行会考虑是否需要进行政策调整。(财联社)

30分钟前

特斯拉晋升迈克尔·斯奈德为能源与充电副总裁

10月26日,职业社交网站LinkedIn显示,特斯拉Megapack高级总监迈克尔·斯奈德(Michael Snyder)已获晋升为能源与充电副总裁。斯奈德于2014年6月加入特斯拉,于2022年8月担任Megapack高级主管,领导公司的Megapack项目。(界面)

30分钟前

机构:三季度全球AMOLED手机面板出货量同比、环比双增长

36氪获悉,10月26日,CINNO Research最新报告指出,随着苹果iPhone16系列等高端旗舰机型的发布,第三季度OLED面板的整体需求持续回升。根据CINNO Research统计数据显示,2024年第三季度全球AMOLED智能手机面板出货量约2.2亿片,同比增长25.3%,环比增长0.9%,同比、环比双增长。从柔性面板出货来看,2024年第三季度全球AMOLED智能手机面板中柔性AMOLED智能手机面板占比76.4%,同比下滑2.3个百分点,环比上升4.2个百分点。

30分钟前

上海机场明日将执行2024年冬春航班计划

36氪获悉,据上海机场集团消息,2024年10月27日至2025年3月29日,上海机场将执行2024年冬春航季航班计划。新航季中,上海机场日均计划执行航班2403架次(其中,浦东机场1627架次、虹桥机场776架次)。日均计划执行国内客运航班1646架次(其中,浦东机场915架次、虹桥机场731架次),同比持平;日均计划执行国际、港澳台客运航班561架次(其中,浦东机场516架次,虹桥机场45架次),同比增长5.2%。

30分钟前

加“新能源”减“红利”,公募基金进攻路线图显现

10月25日,公募基金2024年三季报披露完毕。公募基金最新前十大重仓股出炉,分别是宁德时代、贵州茅台、腾讯控股、立讯精密、美的集团、五粮液、紫金矿业、中际旭创、阳光电源、比亚迪。与2024年二季度末相比,阳光电源、比亚迪新进前十大重仓股,中国海洋石油、迈瑞医疗则退出前十大重仓股行列。随着市场在三季度末快速上涨,基金经理操作更为积极,调仓动作明显。整体来看,公募基金加仓了多只新能源龙头股,同时减持了前期涨幅较高的红利个股。(中证网)

30分钟前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询